aducanumab

A breakthrough in Alzheimer's drug development?

While Alzheimer's disease poses an increasing burden on society, drug development in the field has struggled to keep up...

Alzinova's Alzheimer's candidate challenges with higher specificity

The European Medicines Agency (EMA) recently recommended the refusal of marketing authorization for...

Important step forward for Biogen in Alzheimer's

As BioStock noted last week, the Alzheimer's field is...

AbbVie ends collaboration on Alzheimer's and Parkinson's

Alzheimer's and Parkinson's are two diseases that have long...

Article series on Alzheimer's disease, part II: The research

Alzheimer's is characterized by the toxic accumulation of sticky proteins...

Article series on Alzheimer's disease, part I: Alzheimer's Foundation

Alzheimer's has received a lot of attention recently...

Biogen's failed phase III in Alzheimer's draws Swedish sector colleague with it

Biogen and Eisai suspend development of their Alzheimer's candidate aducanumab...